Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 14/20 | 0.57 |
| ▸ | GSK3B | P49841 | 14/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529920 | 0.93 | GSK3A (0.61) | GSK3AGSK3BRAB9AALDH1A1KDM4E | |
| SCHEMBL5550070 | 0.92 | GSK3A (0.50) | GSK3AGSK3BRAB9AALDH1A1KDM4E | |
| SCHEMBL5549831 | 0.92 | GSK3A (0.50) | GSK3AGSK3BRAB9ALMNAHTT | |
| SCHEMBL5548893 | 0.92 | GSK3A (0.49) | GSK3AGSK3BRAB9AKMT2ALMNA | |
| SCHEMBL3525341 | 0.91 | GSK3B (0.48) | GSK3AGSK3BRAB9ALMNAHTT | |
| SCHEMBL5548604 | 0.90 | GSK3A (0.48) | GSK3AGSK3BRAB9ALMNAHTT | |
| SCHEMBL5548595 | 0.87 | GSK3B (0.48) | GSK3AGSK3BALDH1A1KDM4ELMNA | |
| SCHEMBL3521643 | 0.85 | GSK3A (0.43) | GSK3AGSK3BKMT2ASMN1; SMN2 | |
| SCHEMBL5549009 | 0.85 | GSK3A (0.43) | GSK3AGSK3BRAB9AALDH1A1KDM4E | |
| SCHEMBL3530232 | 0.85 | GSK3A (0.46) | GSK3AGSK3BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709473-B2 | Substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors | PFIZER INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-10-25 | — | — | US | disclosed |
| EP-1678180-B1 | SUBSTITUTED 2H-[1,2,4]TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885RAB9A 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.